Inflammatory bowel disease (IBD): novel approaches for diagnosis and gut microbiota modulation in ulcerative colitis patients

• Grant number: 15/15267-8
• Support Opportunities: Research Projects - Thematic Grants
• Start date: January 01, 2017
• End date: December 31, 2022
• Field of knowledge: Biological Sciences - Pharmacology - Clinical Pharmacology
• Principal Investigator: Luiz Claudio Di Stasi
• Grantee: Luiz Claudio Di Stasi
• Host Institution: Instituto de Biociências (IBB). Universidade Estadual Paulista (UNESP). Campus de Botucatu. Botucatu , SP, Brazil
• Associated researchers: Fabio da Silva Yamashiro ; Fernando Gomes Romeiro ; Josias Rodrigues ; Julio Gálvez Peralta ; Ligia Yukie Sassaki ; Maria Aparecida Marchesan Rodrigues Kobayasi
• Associated scholarship(s): 22/04860-3 - Inflamatory Bowel Disease (IBD): new diagnostic approaches and modulation of the intestinal microbiota in patients with ulcerative colits, BP.TT; 21/02297-7 - Inflammatory Bowel Disease (IBD): new diagnostic approaches and modulation of the intestinal microbiota in patients with ulcerative colitis, BP.IC; 21/01941-0 - In vitro fermentation studies of green dwarf banana (Musa sp AAA) and their prebiotic and modulatory effects on the intestinal microbiota, BP.IC; + associated scholarships 20/06832-1 - Inflammatory bowel disease (IBD): new diagnostic approaches and modulation of the intestinal microbiota in patients with ulcerative colitis, BP.TT; 19/08715-5 - Effect of dietary supplementation with green nanana banana meal in patients with ulcerative colitis, BP.TT; 17/03959-8 - MicroRNAs as diagnosis and prognosis markers of ulcerative colitis and Crohn's disease in patients with inflammatory bowel disease, BP.PD - associated scholarships

Abstract

Inflammatory Bowel disease (IBD) is a chronic inflammatory disorder of gut that includes ulcerative colitis (UC) and Crohn's disease (CD). Although current drugs are only used to control IBD symptoms, the correct differentiation between UC and CD is a determining factor to better choose of pharmacological treatment. In addition, the complex, unclear and inexact aetiology of IBD is a limiting factor that complicates the development of new pharmacologic treatments. Since diagnosis of UC and CD is a serious problem in clinical patient attendance and the absence of pharmacological cure of IBD, the main objectives of our project are 1. to propose a new diagnostic and prognostic tools for UC and CD using microRNAs profile in DII patients and, 2. to evaluate new functional foods as dietary complementary products (Musa sp AAA and Euterpe oleracea) able to modulate intestinal microbiota in UC patients treated with mesalazine. In the first set of experiments, microRNAs profile of IBD patients will be evaluated in order to determine specific colonic microRNAs in patients with UC and CD useful for diagnosis and prognosis of these diseases. In the second set of experiments, active UC patients treated with mesalazine will be submitted to a randomized clinical trial using two dietary complementary products based in Musa sp AAA and Euterpe oleraceae floors, two designed functional foods with proven benefits in pre-clinical studies. In addition, microRNA profile will be performed in the intestinal inflammation induced by DSS (dextran sodium sulphate) and TNBS (trinitrobenzenesulphonic acid), in order to standardize these experimental protocols as UC and CD models. Clinical evaluation, macroscopic and microscopic analysis, biochemical evaluation of cytokine production, microRNA profile, microbiome evaluation, short-chain fatty acids production and other faecal markers will be used to determine the benefits of dietary supplementation with Musa sp AAA and Euterpe oleracea floors in UC patients. (AU)

Scientific publications

(7)

(References retrieved automatically from Web of Science and SciELO through information on FAPESP grants and their corresponding numbers as mentioned in the publications by the authors)

ALMEIDA-JUNIOR, L. D.; CURIMBABA, T. F. S.; CHAGAS, A. S.; QUAGLIO, A. E. V.; DI STASI, L. C.. Dietary intervention with green dwarf banana flour (Musa sp AAA) modulates oxidative stress and colonic SCFAs production in the TNBS model of intestinal inflammation. Journal of Functional Foods, v. 38, n. A, p. 497-504, NOV 2017. (11/50512-2, 15/15267-8)

ALMEIDA-JUNIOR, L. D.; CURIMBABA, T. F. S.; CHAGAS, A. S.; QUAGLIO, A. E. V.; DI STASI, L. C.. Dietary intervention with green dwarf banana flour (Musa sp AAA) modulates oxidative stress and colonic SCFAs production in the TNBS model of intestinal inflammation. Journal of Functional Foods, v. 38, p. 8-pg., 2017-11-01. (15/15267-8, 11/50512-2)

TANIMOTO, ALEXANDRE; WITAICENIS, ALINE; CARUSO, ICARO P.; PIVA, HEMILY M. R.; ARAUJO, GABRIELA C.; MORAES, FABIO R.; FOSSEY, MARCELO C.; CORNELIO, MARINONIO L.; SOUZA, FATIMA P.; DI STASI, LUIZ C.. 4-Methylesculetin, a natural coumarin with intestinal anti-inflammatory activity, elicits a glutathione antioxidant response by different mechanisms. Chemico-Biological Interactions, v. 315, JAN 5 2020. (15/15267-8)

QUAGLIO, V, ANA E.; CRUZ, VINICIUS M.; ALMEIDA-JUNIOR, LUIZ D.; COSTA, CELSO A. R. A.; DI STASI, LUIZ C.. Bidens pilosa (Black Jack) Standardized Extract Ameliorates Acute TNBS-induced Intestinal Inflammation in Rats. Planta Medica, v. 86, n. 5, p. 319-330, MAR 2020. (17/03959-8, 15/15267-8)

COSTA, C. A. R. A.; QUAGLIO, A. E. V.; DI STASI, L. C.. Pfaffia paniculata (Brazilian ginseng) extract modulates Mapk and mucin pathways in intestinal inflammation. Journal of Ethnopharmacology, v. 213, p. 21-25, MAR 1 2018. (15/15267-8)

CURIMBABA, T. F. S.; ALMEIDA-JUNIOR, L. D.; CHAGAS, A. S.; QUAGLIO, A. E. V.; HERCULANO, A. M.; STASI, L. C. DI. Prebiotic, antioxidant and anti-inflammatory properties of edible Amazon fruits. FOOD BIOSCIENCE, v. 36, AUG 2020. (15/15267-8)

ALMEIDA JUNIOR, LUIZ DOMINGUES; VALENCISE QUAGLIO, ANA ELISA; RODRIGUES DE ALMEIDA COSTA, CELSO ACACIO; DI STASI, LUIZ CLAUDIO. Intestinal anti-inflammatory activity of Ground Cherry (Physalis angulata L.) standardized CO2 phytopharmaceutical preparation. WORLD JOURNAL OF GASTROENTEROLOGY, v. 23, n. 24, p. 4369-4380, JUN 28 2017. (11/50512-2, 15/15267-8)